Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency: an extension of a randomized controlled single-blind study.

Cittadini A, Marra AM, Arcopinto M, Bobbio E, Salzano A, Sirico D, Napoli R, Colao A, Longobardi S, Baliga RR, Bossone E, Saccà L

JACC. Heart failure5 Aug 2013Cited by 55 (Europe PMC)

PMID24621936DOI10.1016/j.jchf.2013.04.003PepBankPUB-24621936

Source link PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In growth hormone-deficient patients with heart failure, peak oxygen consumption treatment effects were 7.1 ± 0.7 versus -1.8 ± 0.5 ml/kg/min with control.
In plain wordsIn growth hormone-deficient patients with heart failure, growth hormone improved peak oxygen consumption versus control.
Peptide
HGH (somatotropin)
Outcome
IncreasePeak oxygen consumption
Study
n = 31
Comparator
Standard CHF therapy
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 4 yearsAs given in this study (human).
Measurements
Peak VO2 treatment effect
7.1 ml/kg/min
GH
Peak VO2 variability
0.7 ml/kg/min
GH
Peak VO2 treatment effect
−1.8 ml/kg/min
control
Peak VO2 variability
0.5 ml/kg/min
control
Source sentences
Summary
The treatment effect was 7.1 ± 0.7 ml/kg/min versus -1.8 ± 0.5 ml/kg/min in the GH and control groups, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
In the GH group, peak VO2 improved over the 4-year follow-up.
Summary · context
Fifty-six patients were randomized to receive either GH therapy or standard CHF therapy. Patients were evaluated at baseline and after a 4-year follow-up.
Report a problemFND-2462193601
02HumanRandomized controlled trialEfficacy outcome
In growth hormone-deficient patients with heart failure, ejection fraction increased by 10 ± 3% with growth hormone versus a 2 ± 5% decrease with control.
In plain wordsIn growth hormone-deficient patients with heart failure, growth hormone increased heart ejection fraction versus a decrease with control.
Peptide
HGH (somatotropin)
Outcome
IncreaseLeft ventricular ejection fraction
Study
n = 31
Comparator
Standard CHF therapy
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 4 yearsAs given in this study (human).
Measurements
Ejection fraction change
10%
GH
Ejection fraction variability
3%
GH
Ejection fraction decrease
2%
control
Ejection fraction variability
5%
control
Source sentences
Summary
At 4 years, LV ejection fraction increased by 10 ± 3% in the GH group, whereas it decreased by 2 ± 5% in control patients.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-six patients were randomized to receive either GH therapy or standard CHF therapy. Patients were evaluated at baseline and after a 4-year follow-up.
Report a problemFND-2462193602
03HumanRandomized controlled trialEfficacy outcome
In growth hormone-deficient patients with heart failure, end-systolic volume index treatment effects were -22 ± 6 with growth hormone versus 8 ± 3 with control.
In plain wordsIn growth hormone-deficient patients with heart failure, growth hormone reduced end-systolic volume index versus control.
Peptide
HGH (somatotropin)
Outcome
DecreaseLeft ventricular end-systolic volume index
Study
n = 31
Comparator
Standard CHF therapy
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 4 yearsAs given in this study (human).
Measurements
LV end-systolic volume index treatment effect
−22 ml
GH
Variability
6 ml
GH
LV end-systolic volume index treatment effect
8 ml/m(2)
control
Variability
3 ml/m(2)
control
Source sentences
Summary
The treatment effect on LV end-systolic volume index was -22 ± 6 ml and 8 ± 3 ml/m(2) in the GH and control groups, respectively (all p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-six patients were randomized to receive either GH therapy or standard CHF therapy. Patients were evaluated at baseline and after a 4-year follow-up.
Report a problemFND-2462193603
04HumanNon-randomized trialSafety outcome
In growth hormone-deficient patients with heart failure who received growth hormone, no major adverse events were reported.
In plain wordsIn growth hormone-deficient patients with heart failure who received growth hormone, no major adverse events were reported.
Peptide
HGH (somatotropin)
Outcome
Not applicableMajor adverse events
Study
n: not reported in source
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 4 yearsAs given in this study (human).
Source sentences
Summary
No major adverse events were reported in the patients who received GH.
1 context sentence(design, population, supporting numbers)
Summary · context
Fifty-six patients were randomized to receive either GH therapy or standard CHF therapy. Patients were evaluated at baseline and after a 4-year follow-up.
Report a problemFND-2462193604

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.